Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 3/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AOC1 | P19801 | 5/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956492 | 1.00 | CYP2E1 (0.42) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL29953418 | 0.84 | CYP2E1 (0.45) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL6362005 | 0.84 | CYP2E1 (0.45) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL18362685 | 0.82 | LOXL2 (0.38) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL20519199 | 0.79 | CYP11B2 (0.43) | LMNAAOC1AOC3LOXL2 | |
| SCHEMBL28983721 | 0.79 | CHRNB2 (0.43) | CYP2D6CYP2A6CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL20519418 | 0.77 | GPBAR1 (0.36) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL20519210 | 0.76 | ENPP2 (0.35) | SMN1; SMN2AOC1AOC3LOXL2LIPG | |
| SCHEMBL877689 | 0.75 | CYP2E1 (0.48) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL15476059 | 0.74 | AOC1 (0.31) | AOC1AOC3LOXL2LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| CN-110678466-B | Diazanaphthalenes as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| CN-113454070-A | Cinnoline compounds and their use for the treatment of HPK 1-dependent disorders such as cancer | 豪夫迈·罗氏有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3856724-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3601284-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678466-A | Naphthyridines as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | CYP2E1 2052/4885CYP2C8 2607/4885CYP2D6 3788/4885 |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CYP2E1 3261/4885CYP2C8 3923/4885CYP2D6 3780/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | CYP2E1 3261/4885CYP2C8 3923/4885CYP2D6 3780/4885 |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | CYP2E1 2052/4885CYP2C8 2607/4885CYP2D6 3788/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CYP2E1 3261/4885CYP2C8 3923/4885CYP2D6 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.